A Study of IBR854 Combined With Pazopanib Versus Pazopanib in Advanced Renal Cell Carcinoma

NCT07087158 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Renal Cell Carcinoma (RCC)

Interventions

DRUG: IBR854
DRUG: Pazopanib

Sponsor

Imbioray (Hangzhou) Biomedicine Co., Ltd.